CANAGLIFLOZIN, A SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT-2) BLOCKER, NORMALIZES BLOOD GLUCOSE WITHOUT AFFECTING SYSTEMIC BLOOD PRESSURE, OXIDATIVE STRESS, INTRARENAL ANGIOTENSINOGEN GENE EXPRESSION AND KIDNEY INJURY IN TYPE 1 DIABETIC MICE

被引：0
|
作者：
Chan, John S. D. [1 ]
Chenier, Isabelle [1 ]
Ghosh, Anindya [1 ]
Wu, Chin-Han [1 ]
Lo, Chao-Sheng [1 ]
Zhao, Shuiling [1 ]
Chiasson, Jean-Louis [1 ]
Filep, Janos G. [2 ]
Ingelfinger, Julie R. [3 ]
Zhang, Shao-Ling [1 ]
机构：
[1] CHUM, Res Ctr, Montreal, PQ, Canada
[2] Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ H1T 2M4, Canada
[3] Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2016年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
SP374
引用
收藏
页码：214 / 214
页数：1
相关论文
共 50 条
  • [21] A novel sodium-glucose co-transporter 2 gene (SGLT2) mutation contributes to the abnormal expression of SGLT2 in renal tissues in familial renal glucosuria
    Yu, Lei
    Hou, Ping
    Lv, Ji-Cheng
    Liu, Guo-Ping
    Zhang, Hong
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (11) : 2237 - 2238
  • [22] In Rodents, Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Moderately Increase Blood Ketones thus Amplifying the Effects of Fasting
    Mayoux, Eric W.
    Faessler, Julia
    Hertenberger, Carina
    Mark, Michael
    Luippold, Gerd
    DIABETES, 2016, 65 : A310 - A310
  • [23] Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
    Michael Pfeifer
    Raymond R. Townsend
    Michael J. Davies
    Ujjwala Vijapurkar
    Jimmy Ren
    Cardiovascular Diabetology, 16
  • [24] Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
    Pfeifer, Michael
    Townsend, Raymond R.
    Davies, Michael J.
    Vijapurkar, Ujjwala
    Ren, Jimmy
    CARDIOVASCULAR DIABETOLOGY, 2017, 16
  • [25] A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats
    Kobuchi, Shinji
    Yano, Kyoka
    Ito, Yukako
    Sakaeda, Toshiyuki
    BIOMEDICAL CHROMATOGRAPHY, 2016, 30 (10) : 1549 - 1555
  • [26] Improvement of Vascular Dysfunction, Oxidative Stress, and Glucotoxicity by the Sodium-Glucose Co-transporter 2 Inhibitor Empagliflozin in a Type 2 Diabetes Mellitus Model
    Steven, Sebastian
    Oelze, Matthias
    Schulz, Eberhard
    Mayoux, Eric W.
    Muenzel, Thomas
    Daiber, Andreas
    DIABETES, 2016, 65 : A128 - A128
  • [27] Improvement of diabetes-induced vascular dysfunction, oxidative stress and inflammation in type 2 diabetic ZDF rats by the sodium-glucose co-transporter 2 inhibitor empagliflozin
    Oelze, M.
    Steven, S.
    Kroeller-Schoen, S.
    Kashani, F.
    Roohani, S.
    Welschof, P.
    Weber, A.
    Xia, N.
    Li, H.
    Bottari, S. P.
    Lackner, K. J.
    Wenzel, P.
    Mayoux, E.
    Muenzel, T.
    Daiber, A.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1104 - 1105
  • [28] Effect of sodium glucose Co-transporter 2 inhibitor use on anthropometric measurements and blood glucose in obese and non-obese type 2 diabetic patients
    Dedemen, Busra
    Duman, Tuba Taslamacioglu
    Dedemen, Metin Mert
    Aktas, Gulali
    CLINICAL NUTRITION ESPEN, 2024, 63
  • [29] Inhibition of the Sodium-Glucose Co-Transporter Protein Type 2 Decreases Oxidative Stress and Improves Cardiac Remodeling in Rats with Diabetes Mellitus
    Rosa, Camila Moreno
    Salome Campos, Dijon Henrique
    Reyes, David Rafael
    Pagan, Luana Urbano
    Gomes, Mariana Janini
    Damatto, Felipe
    Henrique Fernandes, Ana Angelica
    Okoshi, Marina Politi
    Okoshi, Katashi
    FASEB JOURNAL, 2016, 30
  • [30] Sodium-glucose co-transporter 2 inhibitors and serum uric acid Re: Mende CW. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Curr Med Res Opin 2017;33:541-51
    Kawada, Tomoyuki
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (02) : 179 - 180
12345